Glucagon-like peptide-1 (GLP-1) receptor agonists

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

Treating people with type 2 diabetes with the triple agonist retatrutide shows promising improvements in both glycemic control and reduction in obesity.

Improved glycemic control and weight loss seen with the coadministration of cagrilintide and semaglutide in a phase 2 trial.

Using liraglutide in people with obesity and prediabetes is a valuable strategy for weight loss, but improvements are greater with caloric restriction alone, suggest study results.

A multifaceted, clinic-level intervention results in a marked increase in the proportion of people with type 2 diabetes and atherosclerotic cardiovascular disease receiving appropriate medications, shows the COORDINATE randomized trial.

A meta-analysis suggests that glucagon-like peptide-1 receptor agonists may help prevent new-onset heart failure in people with type 2 diabetes.

Read more about this decision here

Levels of the inflammatory marker C-reactive protein decrease in people with or without type 2 diabetes taking weekly semaglutide 2.4 mg, shows analysis of three STEP trials.

Click through to read more on this announcement

Semaglutide at a dose of 2.4 mg/week results in substantial weight loss among adolescents with obesity, show the results of the STEP TEENS trial.

A novel triple receptor agonist has demonstrated an acceptable safety profile and promising reductions in blood glucose and bodyweight in a phase 1b trial reported in The Lancet.

People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.

Age, duration of type 2 diabetes, and race may help guide choice of glucose-lowering therapy for individuals with established CVD or those at high risk, say the authors of a systematic review and meta-analysis published in eClinicalMedicine.

The substantial weight loss achieved with weekly semaglutide 2.4 mg is maintained if people continue to take the medication for 2 years, show the STEP 5 results.

The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.

Starting treatment with SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors is associated with a reduction in physical activity levels among some people with type 2 diabetes, researchers report.

The rate of heart failure hospitalization rises more than the rate of major adverse cardiovascular events as vascular risk increases in people with type 2 diabetes, report researchers.

Dulaglutide delivers significant reductions in glucose levels for youths with type 2 diabetes, report the AWARD-PEDS investigators.

The addition of insulin glargine 300 units/mL to glucagon-like peptide-1 receptor agonist therapy in people with type 2 diabetes results in improved glycemic control without increasing risk for hypoglycemia, suggest findings from the real-world DELIVER-G study.